Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Re-dosing Otelixizumab in New T1DM
NCT01222078Phase 2Terminated
- Sponsor
- GSK
- Start
- Nov 2010
- Primary completion
- May 2011
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of otelixizumab in type 1 diabetes mellitus (T1D), sponsored by GSK. Started Nov 2010; status: terminated.
02
Drugs
otelixizumab
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT01222078.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01222078.